Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Celldex Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Alpine Immune Sciences, Inc. and Celldex Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Alpine Immune Sciences saw a nearly tenfold increase in SG&A expenses, starting at approximately $2.3 million and reaching $22.2 million. This represents a significant growth trajectory, reflecting their aggressive expansion strategy.

Conversely, Celldex Therapeutics maintained a more stable SG&A expenditure, peaking at $36 million in 2016 before stabilizing around $31 million by 2023. This suggests a more controlled approach to cost management. While Alpine's expenses grew by over 870%, Celldex's increased by about 50%, indicating different strategic priorities. Understanding these trends offers valuable insights into how biotech firms balance growth and operational efficiency.